Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment
US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...
Drug
AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...
Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...
CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...
Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...
Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer
Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...
CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China
The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech...
Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...
Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...
Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...
Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers
Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...
Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China
France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...
Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...
Humanwell Healthcare’s Recombinant Plasmid Hepatocyte Growth Factor Injection Accepted for NMPA Review
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that the National Medical Products...
Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...
Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...
Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval
Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...
Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324
UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...